Thermo Fisher Scientific

Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale

Retrieved on: 
星期五, 四月 5, 2024
Head, Algorithm, Immunotherapy, University, Neoplasm, PM, Vaccine, Analysis, Navigation, Mutation, Thermo Fisher Scientific, Cancer, Unprecedented, Glioblastoma, Result, Risk, Research, Tumor microenvironment, Antibody, Security (finance), Personalized medicine, PST, Proteomics, AACR, Pancreatic cancer, Ultrahigh, Conversation, Annual general meeting, AQUA, Lung cancer, University of Queensland, MIT, Titan Mare Explorer, Medical imaging

MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.

Key Points: 
  • MARLBOROUGH, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced it will highlight case studies featuring its Spatial Biology 2.0 Solutions that enable unprecedented speed and scale for spatial biology studies at the American Association for Cancer Research (AACR) 2024 Annual Meeting in San Diego, April 5 to 10.
  • Industry-leading capabilities of the company’s spatial biology platforms will be presented during Akoya’s Spotlight Theater, titled “Spatial Biology 2.0: Spatial Insights and Precision Medicine at Unprecedented Scale” on Monday, April 8 at 3 PM (PST).
  • Akoya Biosciences will demonstrate new uses of its PhenoCode Signature Panels for accelerating discovery and validation of spatial biomarkers using the PhenoImager HT 2.0 platform.
  • PhenoImager HT 2.0: Features targeted PhenoCode Signature Panels and onboard spectral unmixing, simplifying biomarker development and validation workflows for large scale studies.

Thermo Fisher Scientific Innovations at Analytica 2024 Optimize Workflows and Enable Precise Analysis Across Life Sciences, Applied and Industrial Markets

Retrieved on: 
星期二, 四月 9, 2024
Technology, Biotechnology, Chemicals, Plastics, Health, Manufacturing, Other Education, Professional Services, Environment, Research, Education, Data Analytics, Hardware, Science, Green Technology, Environmental monitoring, Instrument, Quality control, QA/QC, Conference, Environmental chamber, Pharmacy, LIMS, Thermo Fisher Scientific, Laboratory, Investment, CFR, ULT, Data management, XRD

Analytica 2024 - Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference.

Key Points: 
  • Analytica 2024 - Thermo Fisher Scientific, Inc. is debuting its recently launched innovative products, hosting educational presentations and showcasing live lab demos for customers working in laboratory technology, analysis, biotechnology, and environmental quality during the 2024 Analytica Conference.
  • “Advancements in data analytics and optimized laboratory workflows that enable fast, precise analysis are key to propelling the field of analytical science forward,” said Dan Shine, senior vice president and president, Analytical Instruments, Thermo Fisher.
  • Real-time monitoring with process analytical technology - The Thermo Scientific™ MarqMetrix™ All-In-One Process Raman Analyzer enables real-time, accurate spectral results for in-line, at-line, or on-line process monitoring.
  • For more information regarding Thermo Fisher products and services exhibited at Analytica 2024, please visit the website or booth 101 in hall B1.

The OneLegacy Donate Life Run/Walk and Family Festival Returns to Azusa Pacific University, Celebrating 22 Years of Inspiring Southern Californians to Donate Life

Retrieved on: 
星期一, 四月 8, 2024
Entertainment, Sports, General Health, Events, Concerts, Family, Philanthropy, Consumer, Fund Raising, Foundation, Surgery, Health, Running, Research, Foreign policy, Friends, ABC, Cedars-Sinai Medical Center, Memory, Azusa Pacific University, Thermo Fisher Scientific, City, Hospital, Providence St. Joseph Health, Life, Eye, Golden Joystick Awards, Mexican cuisine, Medical device

“We look forward to welcoming donor families, grateful recipients, living donors and OneLegacy’s hospital and community partners to our 22nd Annual Run/Walk and Family Festival,” said Tom Mone, External Affairs Officer for OneLegacy.

Key Points: 
  • “We look forward to welcoming donor families, grateful recipients, living donors and OneLegacy’s hospital and community partners to our 22nd Annual Run/Walk and Family Festival,” said Tom Mone, External Affairs Officer for OneLegacy.
  • “The OneLegacy Donate Life Run/Walk is a special celebration of the gift of life and the power of organ, eye and tissue donation within our local communities.”
    The OneLegacy Donate Life Run/Walk will include a special opening ceremony, hosted by Phillip Palmer and Gabriela Teissier.
  • 2024 will be the 9th year that team Forever 22 will participate in the OneLegacy Donate Life Run/Walk.
  • All proceeds from the Donate Life Run/Walk will benefit the OneLegacy Foundation, with the goal to enhance OneLegacy’s public education efforts and inspire local communities to donate life.

Thermo Fisher Scientific Launches New ENERGY STAR certified TSX Universal Series ULT Freezers to Deliver Tighter Temperature Control and Faster Recovery Times

Retrieved on: 
星期一, 四月 8, 2024
Other Health, Research, Pharmaceutical, Sustainability, Medical Devices, Environment, Health Technology, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, ACT, Temperature, Thermo Fisher Scientific, Laboratory, GMP, TSX, ULT, Multimedia, ISO, Medical device

Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.

Key Points: 
  • Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.
  • With enhancements to performance, user experience and energy efficiency, the Thermo Scientific™ TSX™ Universal Series ULT Freezers seamlessly adapt to scientists’ workflows across a variety of lab settings, marking a new era in performance, reliability, and sustainability.
  • With Universal V-Drive technology, tighter control, faster recovery times, universal voltage, and an expanded setpoint range, the TSX Universal Series seamlessly adapts to diverse workflows, from high-use academic labs to longer-term storage facilities.
  • Delivering both industry leading performance and energy efficiency, the TSX Universal Series allows labs to meet their sustainability goals without sacrificing performance.

Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets™.

Retrieved on: 
星期一, 四月 8, 2024
Sepsis, High, Development, Growth, Fungal infection, Abbott Laboratories, Incidence, Thermo Fisher Scientific, Danaher Corporation, Biomarker, Sysmex Corporation, Evolution, Pulse, Roche, Service, Vanderbilt University Medical Center, EKF Diagnostics, Medical device

Key Market Players of Sepsis Diagnostics Industry:

Key Points: 
  • Key Market Players of Sepsis Diagnostics Industry:
    As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland).
  • Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155
    Sepsis Diagnostics Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

Sepsis Diagnostics Market Worth $890 million | MarketsandMarkets™.

Retrieved on: 
星期一, 四月 8, 2024
Sepsis, High, Development, Growth, Fungal infection, Abbott Laboratories, Incidence, Thermo Fisher Scientific, Danaher Corporation, Biomarker, Evolution, Pulse, Roche, Service, Vanderbilt University Medical Center, EKF Diagnostics, Medical device

Key Market Players of Sepsis Diagnostics Industry:

Key Points: 
  • Key Market Players of Sepsis Diagnostics Industry:
    As of 2023, prominent players in sepsis diagnostics are bioMérieux (France), Becton Dickinson Company (US), Danaher Corporation (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland).
  • Other players include T2 Biosystems (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), among others.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=92673155
    Sepsis Diagnostics Market - Key Benefits of Buying the Report:
    The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share.
  • Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

Clario appoints Julia James as Chief Legal and Administrative Officer

Retrieved on: 
星期一, 四月 8, 2024
Clinical research, Health, General counsel, Civil Service (United Kingdom), Thermo Fisher Scientific, Patient, Acquisition, Woman, Clinical trial, Ecosystem, PPD

PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the appointment of Julia James as the company's Chief Legal and Administrative Officer. This appointment bolsters Clario's strategic focus on improving the customer experience and differentiating its offerings.  

Key Points: 
  • Legal and compliance expert Julia James, previously with Thermo Fisher Scientific, joins Clario to drive legal and compliance strategy
    PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Clario , a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the appointment of Julia James as the company's Chief Legal and Administrative Officer.
  • "We are excited to welcome Julia James to Clario," said Chris Fikry, M.D., Chief Executive Officer at Clario.
  • Julia spent more than 15 years in various legal leadership roles at PPD and, prior to that, worked for the international law firm Clifford Chance in both London and Dubai.
  • "Clario plays a pivotal role in the clinical trial ecosystem through the generation of the highest quality evidence and developing transformative technologies," she said.

Clario appoints Julia James as Chief Legal and Administrative Officer

Retrieved on: 
星期一, 四月 8, 2024
Clinical research, Health, General counsel, Civil Service (United Kingdom), Thermo Fisher Scientific, Patient, Acquisition, Woman, Clinical trial, Ecosystem, PPD

PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Clario, a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the appointment of Julia James as the company's Chief Legal and Administrative Officer. This appointment bolsters Clario's strategic focus on improving the customer experience and differentiating its offerings.  

Key Points: 
  • Legal and compliance expert Julia James, previously with Thermo Fisher Scientific, joins Clario to drive legal and compliance strategy
    PHILADELPHIA, April 8, 2024 /PRNewswire/ -- Clario , a healthcare research and technology company that delivers the leading endpoint technology solutions for clinical trials, today announced the appointment of Julia James as the company's Chief Legal and Administrative Officer.
  • "We are excited to welcome Julia James to Clario," said Chris Fikry, M.D., Chief Executive Officer at Clario.
  • Julia spent more than 15 years in various legal leadership roles at PPD and, prior to that, worked for the international law firm Clifford Chance in both London and Dubai.
  • "Clario plays a pivotal role in the clinical trial ecosystem through the generation of the highest quality evidence and developing transformative technologies," she said.

Olink reports fourth quarter and full year 2023 financial results

Retrieved on: 
星期一, 三月 25, 2024
Signature, Growth, Thermo Fisher Scientific, Row, Research, Acquisition, Wall, Investment, Geography, Video game

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023.

Key Points: 
  • UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023.
  • Analysis services revenue for the fourth quarter of 2023 was $23.2 million, as compared to $23.4 million for the fourth quarter of 2022.
  • Other revenue was $5.7 million for the fourth quarter of 2023, as compared to $3.9 million for the fourth quarter of 2022.
  • Reported gross profit was $48.7 million in the fourth quarter of 2023, as compared to $43.1 million in the fourth quarter of 2022.

Repligen Appoints Maggie A. Pax to Board of Directors

Retrieved on: 
星期二, 三月 19, 2024
College, Innovation, Growth, Life Technologies, Repligen, Business, MIT, Thermo Fisher Scientific, Harvard Business School, Strategic planning, Business development, Acquisition, Massachusetts Institute of Technology, MBA, Marketing, Holy Cross, Alimera Sciences, Corporation, Management

WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.

Key Points: 
  • WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax.
  • Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies.
  • Karen A. Dawes, Chairperson of the Board of Directors for Repligen, said, “We’re very happy to welcome Maggie Pax as a terrific addition to the Repligen Board with extensive experience in the life sciences industry.
  • Hunt, Chief Executive Officer for Repligen said, “Maggie understands first-hand the drivers of growth for our industry and has touched many of the focus areas for Repligen: key account programs, continuous innovation and M&A integration.